News & Events

News

AM1476 Granted Orphan Drug Designation in the US and EU for Treatment of Systemic Sclerosis

2024-02-05

Read more

Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

2023-05-23

Read more

Events

14-16 MARCH 2024

PRAGUE, CZECH REPUBLIC

8th Systemic Sclerosis World Congress

Dr. Wenglén, Head of Research, will present the abstract: “AM1476 – A Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Both Pulmonary and Dermal Fibrosis in the Chronic Graft Versus Host Disease Model of Systemic Sclerosis“ on Friday, March 15, 2024 at 18:30 (CET).

Read more